CEL-SCI

CEL-SCI has begun a global, registration‑relevant confirmatory trial of Multikine as a neoadjuvant treatment for resectable, locally advanced head and neck squamous cell carcinomas. About 212 patients in the US, Europe, Asia and South America are expected to participate; Orient EuroPharma is leading and funding recruitment in Taiwan. Earlier phase‑3 data showed a 5‑year overall survival rate of 73% in the target cohort versus 45% with standard therapy. Multikine has orphan drug designation but is not approved. The company remains under financial pressure despite the trial start (current ratio 0.6; negative levered free cash flow of $16.7 million), though analysts see significant upside potential for the stock. » More on de.investing.com

CEL-SCI placed 6,000,000 common shares at $1.20 per share, generating gross proceeds of approximately $7.2 million. ThinkEquity was the sole placement agent. The company intends to use the funds to further develop candidate Multikine, for general corporate purposes and working capital. CEL-SCI reported negative free cash flow of about $17 million over the last twelve months and a market capitalization of roughly $9.87 million; an S-1 registration became effective on May 11, 2026. » More on de.investing.com

CEL-SCI has entered a partnership with Amarox to pursue regulatory approval and potential commercialisation of Multikine in Saudi Arabia, with an option to expand to the Gulf states. After the SFDA grants Breakthrough Medicine Designation, the partners will split net proceeds from Saudi sales equally; Amarox will lead the local regulatory process and, upon approval, receive exclusive sales rights for head and neck cancers. CEL-SCI retains all IP, manufacturing and global rights to Multikine; the option covers Bahrain, Kuwait, Oman, Qatar and the UAE. The company is under significant financial pressure with a low market capitalisation and negative EBITDA, while Multikine remains in clinical trials and is not yet approved for sale. » More on de.investing.com